Letybo (Botulinum Toxin Type A)

Letybo, a botulinum toxin type A, acts on the neuromuscular junction to reduce excessive muscle activity in several clinical settings.

• Focal muscle spasticity: reduces involuntary muscle contractions and improves functional movement.
• Cervical dystonia: alleviates abnormal neck muscle contractions, decreasing pain and abnormal head posture.
• Facial wrinkles (glabellar lines): smooths dynamic facial lines by relaxing the underlying facial muscles.

• Botulinum toxin type A is a protein neurotoxin that cleaves the SNAP‑25 component of the SNARE complex in presynaptic nerve terminals. This enzymatic action blocks the release of acetylcholine at the neuromuscular junction, preventing muscle fiber activation and producing a temporary, localized paralysis of the targeted muscle.

Adverse reactions to Letybo are generally related to the pharmacologic action of the toxin and the injection procedure.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Bruising: localized discoloration due to minor bleeding.
• Headache: transient headache following injection.
• Localized muscle weakness: temporary reduction in strength of nearby muscles.
• Flu‑like symptoms: mild fever, fatigue, or malaise.
• Dry mouth: reduced salivation after treatment.

Serious or Rare Side Effects

• Dysphagia: difficulty swallowing that may require medical attention.
• Respiratory compromise: weakness of respiratory muscles leading to breathing difficulty.
• Allergic reaction or anaphylaxis: signs include rash, itching, swelling, or severe breathing problems.
• Spread of toxin effect: botulism‑like symptoms such as generalized weakness, vision changes, or drooping eyelids.
• Urinary retention: difficulty emptying the bladder.
• Vision changes: blurred vision or double vision.

Before using Letybo, several safety considerations should be reviewed.

• Pregnancy: safety not established; avoid unless the potential benefit justifies the risk.
• Breastfeeding: unknown excretion in milk; consider discontinuation during nursing.
• Known hypersensitivity: contraindicated in patients with allergy to botulinum toxin or its excipients.
• Neuromuscular disorders: patients with myasthenia gravis or Lambert‑Eaton syndrome may experience exaggerated weakness.
• Infection at injection site: postpone administration until the area is clear of infection.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Letybo may interact with other medications that influence neuromuscular transmission.

Major Interactions (Avoid)

• Aminoglycoside antibiotics (e.g., gentamicin): can potentiate neuromuscular blockade.
• General anesthetics such as succinylcholine: increase risk of prolonged paralysis.
• Concurrent use of other botulinum toxin products: cumulative systemic toxicity.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may reduce the clinical effect of the toxin.
• Calcium channel blockers: possible additive effect on muscle weakness.
• Muscle relaxants (e.g., baclofen): may enhance overall muscle relaxation.